Christine A. Ciunci, MD MSCE
Associate Professor of Clinical Medicine (Hematology-Oncology)
Attending , Hospital of the University of Pennsylvania
Attending , Penn Presbyterian Medical Center
Physician Lead for the Cancer Service Line, Penn Presbyterian Medical Center
Chief of Hematology and Oncology , Penn Presbyterian Medical Center
Physician Lead for PPMC Oncology Clinical Research Program , Penn Presbyterian Medical Center
Department: Medicine
Contact information
Abramson Cancer Center
Penn Presbyterian Medical Center
Pavilion for Advanced Care, 1st Floor
51 N 39th Street
Philadelphia, PA 19104
Penn Presbyterian Medical Center
Pavilion for Advanced Care, 1st Floor
51 N 39th Street
Philadelphia, PA 19104
Office: 215-662-9801
Fax: 2152433249
Fax: 2152433249
Education:
BS (Biology)
Ursinus College, 2004.
MD (Medicine)
Temple University, 2008.
MSCE (MSCE)
University of Pennsylvania School of Medicine, 2014.
Permanent linkBS (Biology)
Ursinus College, 2004.
MD (Medicine)
Temple University, 2008.
MSCE (MSCE)
University of Pennsylvania School of Medicine, 2014.
Description of Clinical Expertise
thoracic malignancieslung cancer
occult primary
Description of Research Expertise
thoracic malignancieslung cancer
Selected Publications
Christine A Ciunci 1, Jacob B Reibel 2, Tracey L Evans 3, Rosemarie Mick 2, Joshua M Bauml 2, Charu Aggarwal 2, Melina E Marmarelis 2, Aditi P Singh 2, Christopher D'Avella 2, Roger B Cohen 2, Corey J Langer 2: Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Clin Lung Cancer 2022.Singh, Aditi P; Berman, Abigail T; Marmarelis, Melina E; Haas, Andrew R; Feigenberg, Steven J; Braun, Jennifer; Ciunci, Christine A; Bauml, Joshua M; Cohen, Roger B; Kucharczuk, John C; Shulman, Lawrence N; Langer, Corey J; Aggarwal, Charu.: Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract 16(9): 579-586, Sep 2020.
Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, Yee SS, Christensen TE, LaRiviere MJ, Silva BA, Banks KC, Nagy RJ, Helman E, Berman AT, Ciunci CA, Singh AP, Wasser JS, Bauml JM, Langer CJ, Cohen RB, Carpenter EL.: Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 26(10): 2354-2361, May 2020.
Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT.: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC. Int J Radiat Oncol Biol Phys. 106(2): 358-68, Feb 1 2020 Notes: DOI: 10.1016/j.ijrobp.2019.10.019.
Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.: Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. Jul 11 2019 Notes: doi: 10.1001/jamaoncol.2019.1449. [Epub ahead of print]
Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 111(5): 490-497, May 2019.
Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.: Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 5(2): 173-180, Feb 1 2019.
Bange E, Marmarelis ME, Hwang WT, Yang YX, Thompson JC, Rosenbaum J, Bauml JM, Ciunci C, Alley EW, Cohen RB, Langer CJ, Carpenter E, Aggarwal C.: Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 3, 2019 Notes: doi: 10.1200/PO.18.00326. Epub 2019 May 10.
Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.: Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol Aug 31 2018 Notes: Epub ahead of print, doi: 10.1200/PO.18.00107.
Evans T, Ciunci C, Hertan L, Gomez D.: Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res. 6(2): 119-130, Apr 2017.